What the business is, and whether it's a good one at a fair price.
Manufactures and markets pharmaceutical formulations across four primary geographies: India, the United States, emerging markets, and the rest of the world. India formulations are the largest stream, with Q1 FY27 sales of Rs 54,749m and the #1 position in the Indian Pharmaceutical Market at 8.5% share. The US business reported US$427m in Q1 FY27 (-9.7% YoY), split between generics under pricing pressure from Lenalidomide erosion and specialty Innovative Medicines, which crossed US$1bn in US sales in FY26 and is now larger than US generics. Global Innovative Medicines, led by Ilumya (IL-23 immunology biologic), Odomzo, Leqselvi (alopecia), and Unloxcyt (oncology), contributed 21.9% of Q1 FY27 sales and grew 12.4% YoY at US$351m. Emerging markets generated US$311m in Q1 FY27 (+4.2%) and ROW generated US$218m. It is also the #2 generic Semaglutide injectable player in India, with approvals secured in Brazil and South Africa. The pending Organon acquisition (closing targeted Q4 FY27) would add a women's health and established brands portfolio, and Innovcare Lifesciences was acquired for Rs 271.2 crores to strengthen the India product range.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SUN PHARMACEUTICAL IND L's filed financials and exchange disclosures
SUN PHARMACEUTICAL IND L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SUNPHARMA.
Yes. Over the trailing twelve months SUN PHARMACEUTICAL IND L reported a net profit of ₹12,117 Cr on revenue of ₹59,911 Cr.
Yes. The dividend yield is 0.89% at the current price. It paid out 34% of its profit as dividend in FY26.
Effectively yes. It holds ₹5,689 Cr more cash than debt. Debt stands at 0.05× equity.
On trailing P/E, SUN PHARMACEUTICAL IND L ranks 101 of 169 in Pharmaceuticals — cheaper than 41% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SUN PHARMACEUTICAL IND L moves 0.62% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SUN PHARMACEUTICAL IND L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
